Plasma IL-6, its soluble receptors and F-2-isoprostanes at rest and during exercise in chronic fatigue syndrome

TY - JOUR

T1 - Plasma IL-6, its soluble receptors and F-2-isoprostanes at rest and during exercise in chronic fatigue syndrome

AU - Robinson, M.

AU - Gray, S. R.

AU - Watson, M. S.

AU - Kennedy, G.

AU - Hill, A.

AU - Belch, J. J. F.

AU - Nimmo, M. A.

PY - 2010/4

Y1 - 2010/4

N2 - The aim of the current study was to investigate the levels of interleukin-6 (IL-6), its soluble receptors (sIL-6R and sgp130) and F-2-isoprostanes, at rest and during exercise, in patients with chronic fatigue syndrome (CFS). Six male CFS patients and six healthy controls performed an incremental exercise test to exhaustion and a submaximal exercise bout to exhaustion. Blood samples taken in the submaximal test at rest, immediately post-exercise and 24 h post-exercise were analyzed for IL-6, sIL-6R, sgp130 and F-2-isoprostanes. A further 33 CFS and 33 healthy control participants gave a resting blood sample for IL-6 and sIL-6R measurement. During the incremental exercise test only power output at the lactate threshold was lower (P < 0.05) in the CFS group. F-2-isoprostanes were higher (P < 0.05) in CFS patients at rest and this difference persisted immediately and 24 h post-exercise. The exercise study found no differences in IL-6, sIL-6R or sgp130 at any time point between groups. In the larger resting group, there were no differences in IL-6 and sIL-6R between CFS and control groups. This investigation has demonstrated that patients with CFS do not have altered plasma levels of IL-6, sIL-6R or sgp130 either at rest or following exercise. F-2-isoprostanes, however, were consistently higher in CFS patients.

AB - The aim of the current study was to investigate the levels of interleukin-6 (IL-6), its soluble receptors (sIL-6R and sgp130) and F-2-isoprostanes, at rest and during exercise, in patients with chronic fatigue syndrome (CFS). Six male CFS patients and six healthy controls performed an incremental exercise test to exhaustion and a submaximal exercise bout to exhaustion. Blood samples taken in the submaximal test at rest, immediately post-exercise and 24 h post-exercise were analyzed for IL-6, sIL-6R, sgp130 and F-2-isoprostanes. A further 33 CFS and 33 healthy control participants gave a resting blood sample for IL-6 and sIL-6R measurement. During the incremental exercise test only power output at the lactate threshold was lower (P < 0.05) in the CFS group. F-2-isoprostanes were higher (P < 0.05) in CFS patients at rest and this difference persisted immediately and 24 h post-exercise. The exercise study found no differences in IL-6, sIL-6R or sgp130 at any time point between groups. In the larger resting group, there were no differences in IL-6 and sIL-6R between CFS and control groups. This investigation has demonstrated that patients with CFS do not have altered plasma levels of IL-6, sIL-6R or sgp130 either at rest or following exercise. F-2-isoprostanes, however, were consistently higher in CFS patients.

KW - oxidative stress

KW - cytokines

KW - OXIDATIVE STRESS

KW - INTERLEUKIN-6

KW - HUMANS

KW - CYTOKINE

KW - GP130

KW - PERFORMANCE

KW - EXPRESSION

KW - HEALTHY

KW - COMPLEX

KW - PEOPLE

U2 - 10.1111/j.1600-0838.2009.00895.x

DO - 10.1111/j.1600-0838.2009.00895.x

M3 - Article

C2 - 19422646

SN - 0905-7188

VL - 20

SP - 282

EP - 290

JO - Scandinavian Journal of Medicine & Science in Sports

JF - Scandinavian Journal of Medicine & Science in Sports

IS - 2

ER -